UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000017968
Receipt No. R000019516
Scientific Title Retinal sensitivity in branch retinal vein occlusion after anti-VEGF therapy
Date of disclosure of the study information 2015/06/19
Last modified on 2019/10/25

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Retinal sensitivity in branch retinal vein occlusion after anti-VEGF therapy
Acronym Retinal sensitivity in BRVO after anti-VEGF therapy
Scientific Title Retinal sensitivity in branch retinal vein occlusion after anti-VEGF therapy
Scientific Title:Acronym Retinal sensitivity in BRVO after anti-VEGF therapy
Region
Japan

Condition
Condition Branch retinal vein occlusion
Classification by specialty
Ophthalmology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To compare the changes in retinal sensitivity after ranibizumab therapy or combination theraphy of ranibizumab and laser photocoagulation in eyes with branch retinal vein occlusion.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Retinal sensitivity at 12 months
Key secondary outcomes

Base
Study type

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Open -no one is blinded
Control Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine Device,equipment Maneuver
Interventions/Control_1 Ranibizumab (Lucentis) intravitreal injection is performed at baseline. Measurement of the best corrected visual acuity and foveal thickness using optical coherence tomography are performed monthly. Ranibizumab (Lucentis) intravitreal injection is performed when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers.
Interventions/Control_2 Ranibizumab (Lucentis) intravitreal injection is performed at baseline. Measurement of the best corrected visual acuity and foveal thickness using optical coherence tomography are performed monthly. Ranibizumab (Lucentis) intravitreal injection is performed when visual acuity is less than 1.0 and foveal thickness is more than 250micrometers. Macular laser photocoagulation will be performed when visual acuity is less than 1.0 and foveal thickness is more than 250micrometers at month 3 and month 9.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
18 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria Treatment naive patients of branch retinal vein occlusion with visual acuity of less than 1.0 and macular edema of more than 250 micrometers in foveal thickness.
Key exclusion criteria Patients with history of treatment for branch retinal vein occlusion, possibility of pregnancy, allergy for ranibizumab, intraocular infection or severe inflammation will be excluded.
Target sample size 50

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Akira Ojima
Organization Fukushima Medical University
Division name Department of Ophthalmology
Zip code
Address 1 Hikarigaoka, Fukushima, Japan
TEL 024-548-2111
Email ao@fmu.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Akira Ojima
Organization Fukushima Medical University
Division name Department of Ophthalmology
Zip code
Address 1 Hikarigaoka, Fukushima, Japan
TEL 024-548-2111
Homepage URL
Email ao@fmu.ac.jp

Sponsor
Institute Department of Ophthalmology, Fukushima Medical University
Institute
Department

Funding Source
Organization Novartis Pharmaceuticals Japan
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2015 Year 06 Month 19 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2015 Year 06 Month 19 Day
Date of IRB
2014 Year 12 Month 01 Day
Anticipated trial start date
2015 Year 06 Month 19 Day
Last follow-up date
2018 Year 03 Month 31 Day
Date of closure to data entry
2018 Year 03 Month 31 Day
Date trial data considered complete
2018 Year 11 Month 30 Day
Date analysis concluded
2018 Year 12 Month 25 Day

Other
Other related information

Management information
Registered date
2015 Year 06 Month 18 Day
Last modified on
2019 Year 10 Month 25 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019516

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.